CoChat
Sign Up
Cited by 32Parkinson's Disease Mechanisms and TreatmentsDrug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Association between MDR1 gene polymorphisms and Parkinson's disease in Asian and Caucasian populations: a meta-analysis

Ahmed, Shiek S.S.J., Husain, R.S. Akram, Kumar, Suresh, Ramakrishnan, V.·2016·Journal of the Neurological Sciences
DOI 10.1016/j.jns.2016.07.041
Open this paper in CoChat — free account

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disease, its etiology is largely unknown. Studies demonstrate the association of genetic and environment factors in causing neuronal degeneration. Reports suggest that the multi-drug resistance gene (MDR1) plays a vital role in preventing the toxic substance in entering the brain, which is associated with PD. However, the association between the MDR1 polymorphisms (C1236T and C3435T) and its susceptibility to PD is inconclusive. Meta analysis was carried by retrieving literatures from databases to search the case-control studies on the associations between the MRD1 polymorphisms and PD. The pooled odds ratios (ORs) and its 95% confidence intervals (CIs) were calculated using fixed and random model to determine the association between the polymorphisms and PD susceptibility. Significant association was noticed for C1236T polymorphism and PD risk in the recessive model OR=0.80, 95% CI=0.66-0.97. Further, ethnicity based analysis showed significant association for C1236T in allelic model of Asian population and also in the recessive models of both Asian and Caucasian populations. However, insignificant associations were noticed for C3435T in all the four models. Overall, the analysis suggested that MDR1 C1236T polymorphism substantially contribute to Parkinson's disease in the recessive genetic model.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jns.2016.07.041

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 44

  1. Brown, 2005, Neurodegenerative diseases: an overview of environmental risk factors, Environ. Health Perspect., 113, 1250, 10.1289/ehp.7567 · DOI
  2. Goldenberg, 2008, Medical Management of Parkinson's disease, Pharm. Ther., 33, 590
  3. Tsuboi, 2012, Environmental-genetic interactions in the pathogenesis of Parkinson's disease, Exp. Neurobiol., 21, 123, 10.5607/en.2012.21.3.123 · DOI
  4. Manthripragada, 2010, Paraoxonase 1 (PON1), agricultural organophosphate exposure, and Parkinson disease, Epidemiology, 21, 87, 10.1097/EDE.0b013e3181c15ec6 · DOI
  5. Zanger, 2013, Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol. Ther., 138, 103, 10.1016/j.pharmthera.2012.12.007 · DOI · Paper page
  6. Iskakova, 2016, Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan, BMC Genet., 17, 23, 10.1186/s12863-016-0329-x · DOI
  7. Umamaheswaran, 2014, Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective, Indian J. Med. Res., 139, 27
  8. Migliore, 2009, Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases, Mutat. Res. Fundam. Mol. Mech. Mutagen., 667, 82, 10.1016/j.mrfmmm.2008.10.011 · DOI
  9. O'Brien, 2012, Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings, Br. J. Pharmacol., 165, 289, 10.1111/j.1476-5381.2011.01557.x · DOI
  10. Yasui-Furukori, 2006, Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 30, 286, 10.1016/j.pnpbp.2005.06.019 · DOI
  11. Cecchelli, 2007, Modelling of the blood-brain barrier in drug discovery and development, Nat. Rev. Drug Discov., 6, 650, 10.1038/nrd2368 · DOI
  12. Marzolini, 2004, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin. Pharmacol. Ther., 75, 13, 10.1016/j.clpt.2003.09.012 · DOI
  13. Woodahl, 2004, The role of MDR1 genetic polymorphisms in inter individual variability in P-glycoprotein expression and function, Curr. Drug Metab., 5, 11, 10.2174/1389200043489108 · DOI
  14. Tanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J. Pharmacol. Exp. Ther., 297, 1137, 10.1016/S0022-3565(24)29643-9 · DOI
  15. Li, 2006, MDR1 gene polymorphisms and clinical relevance, Yi Chuan Xue Bao, Acta Genet. Sin., 33, 93
  16. Funke, 2009, Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients, J. Neural Transm., 116, 443, 10.1007/s00702-009-0196-y · DOI
  17. Tan, 2005, Effect of MDR1 haplotype on risk of Parkinson disease, Arch. Neurol., 62, 460, 10.1001/archneur.62.3.460 · DOI
  18. Kiyohara, 2013, MDR1 C3435T polymorphism and interaction with environmental factors in risk of parkinson's disease: a case-control study in Japan, Drug Metabol. Pharmacokinet., 28, 138, 10.2133/dmpk.DMPK-12-RG-075 · DOI
  19. Lee, 2004, MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese, J. Med. Genet., 41, e60, 10.1136/jmg.2003.013003 · DOI
  20. Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur. J. Epidemiol., 25, 603, 10.1007/s10654-010-9491-z · DOI · Paper page
  21. Ziegler, 2011, Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis, Breast Cancer Res. Treat., 128, 197, 10.1007/s10549-010-1295-z · DOI
  22. DerSimonian, 1986, Meta-analysis in clinical trials, Control. Clin. Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  23. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ (Clin. Res. Ed.), 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  24. Lek, 2015, Analysis of protein-coding genetic variation in 60,706 humans, bioRxiv
  25. Brinza, 2006, Case (control)-free multi-SNP combinations in case-control studies, Algorithmic Biol.
  26. Westerlund, 2009, Association of a polymorphism in the ABCB1 gene with Parkinson's disease, Parkinsonism Relat. Disord., 15, 422, 10.1016/j.parkreldis.2008.11.010 · DOI
  27. Momose, 2002, Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms, Ann. Neurol., 51, 133, 10.1002/ana.10079 · DOI
  28. Dutheil, 2010, Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease, Arch. Neurol., 67, 739, 10.1001/archneurol.2010.101 · DOI
  29. Tan, 2004, Analysis of MDR1 haplotypes in Parkinson's disease in a white population, Neurosci. Lett., 372, 240, 10.1016/j.neulet.2004.09.046 · DOI
  30. Zschiedrich, 2009, MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?, J. Neurol., 256, 115, 10.1007/s00415-009-0089-x · DOI
  31. Drozdzik, 2003, Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease, Pharmacogenetics, 13, 259, 10.1097/00008571-200305000-00004 · DOI
  32. Furuno, 2002, Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease, Pharmacogenetics, 12, 529, 10.1097/00008571-200210000-00004 · DOI · Paper page
  33. Cannon, 2011, The role of environmental exposures in neurodegeneration and neurodegenerative diseases, Toxicol. Sci., 124, 225, 10.1093/toxsci/kfr239 · DOI
  34. Chin-Chan, 2015, Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases, Front. Cell. Neurosci., 9, 124, 10.3389/fncel.2015.00124 · DOI
  35. Fulda, 2010, Cellular stress responses: cell survival and cell death, Int. J. Cell Biol., 20, 214
  36. Modgil, 2014, Role of early life exposure and environment on neuro-degeneration: implications on brain disorders, Transl. Neurodegener., 3, 9, 10.1186/2047-9158-3-9 · DOI
  37. Girardin, 2006, Membrane transporter proteins: a challenge for CNS drug development, Dialogues Clin. Neurosci., 8, 311, 10.31887/DCNS.2006.8.3/fgirardin · DOI
  38. Loscher, 2005, Blood-brain barrier active efflux transporters: ATP-binding cassette gene family, NeuroRx, 2, 86, 10.1602/neurorx.2.1.86 · DOI
  39. Linardi, 2006, Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs, Ciênc. Rural, 36, 336, 10.1590/S0103-84782006000100056 · DOI
  40. Gandhi, 2012, Drug disposition in pathophysiological conditions, Curr. Drug Metab., 13, 1327, 10.2174/138920012803341302 · DOI
  41. Alavijeh, 2005, Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery, NeuroRx, 2, 554, 10.1602/neurorx.2.4.554 · DOI
  42. Klaassen, 2010, Xenobiotic, bile acid, and cholesterol transporters: function and regulation, Pharmacol. Rev., 62, 1, 10.1124/pr.109.002014 · DOI
  43. Chen, 2009, Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR, J. Clin. Lab. Anal., 23, 110, 10.1002/jcla.20299 · DOI
  44. Lill, 2012, Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PD Gene database, PLoS Genet., 8, e1002548, 10.1371/journal.pgen.1002548 · DOI

Cited by

Sorted by citations

See all 32

Metadata

Authors
Ahmed, S. S. S. J., Husain, R. S. A., Kumar, S., & Ramakrishnan, V.
Affiliations
  • Chettinad Academy of Research and Education (IN)
  • Bharath University (IN)
ORCID
Venue
Journal of the Neurological Sciences
Publisher
Elsevier BV
Published
2016-09
Volume
368
Pages
255-262
ISSN
0022-510X (ISSN-L)
DOI
10.1016/j.jns.2016.07.041
OpenAlex
W2484686817
Cited by
32
References
1
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 4
FWCI
0.60
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the Neurological Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
Chettinad Academy of Research and Education
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
Parkinson's disease, MDR1 gene, P-glycoprotein, C1236T polymorphism, C3435T polymorphism, genetic susceptibility, ethnic differences, Asian populations, Caucasian population, recessive genetic model
MeSH terms
Gene Frequency, Humans, Parkinson Disease, Databases, Bibliographic, ATP Binding Cassette Transporter, Subfamily B, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, White People, Asian People, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review